Tests inebilizumab in children with neuromyelitis optica spectrum disorder

Trial details

Who runs it

Amgen

Trial code

NCT05549258EU 2023-510007-22-00

Record updated

5 December 2025

Original description

A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to < 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin [Ig]G).Read full original descriptionShow less

An Open-Label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to < 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin [Ig]G).

Inclusion: Male or female participants, minimum body weight of 15 kg, age 2 to < 18 years at the time of screening; Positive serum anti-AQP4-IgG result at screening and diagnosed with NMOSD according to the criteria of Wingerchuk et al, 2015; Documented history of one or more NMOSD acute relapses within the last year, or 2 or more NMOSD acute relapses within 2 years prior to screening.

Exclusion: Any condition that, in the opinion of the Investigator, would interfere with the evaluation or administration of the Investigational Product or interpretation of participant safety or study results; Concurrent/previous enrollment in another clinical study involving an investigational treatment within 4 weeks or 5 published half-lives of the investigational treatment, whichever is the longer, prior to Day 1; Receipt of the following at any time prior to Day 1:; Alemtuzumab; Total lymphoid irradiation; Bone marrow transplant; T-cell vaccination therapy; Receipt of intravenous immunoglobulin (IVIG) within one month prior to Day 1; Receipt of any of the following within 2 months prior to Day 1:; Cyclosporine; Methotrexate; Mitoxantrone; Cyclophosphamide; Tocilizumab; Satralizumab; Eculizumab; Receipt of natalizumab (Tysabri®) within 6 months prior to Day 1; Diagnosed with a concurrent autoimmune disease that is uncontrolled (unless approved by the medical monitor); Recent receipt of live/attenuated vaccine or blood transfusion; Receipt of any of the following:; Any live or attenuated vaccine within 4 weeks prior to Day 1 (administration of killed vaccines and nucleoside-modified mRNA-based vaccines is acceptable; the Sponsor recommends that Investigators ensure all participants are up to date on required vaccinations prior to study entry); Bacillus Calmette Guérin vaccine within one year of screening; Blood transfusion within 4 weeks prior to screening or during screening; Clinically significant serious active or chronic viral, bacterial, or fungal infection that requires treatment with anti-infectives, hospitalization, or, in the Investigator's opinion, represents an additional risk to the participant, within 2 months prior to Day 1; Known history of congenital or acquired immunodeficiency (e.g., due to human immunodeficiency virus [HIV] infection, splenectomy, immunosuppression-related or idiopathic T-cell deficiencies) that predisposes the participant to infection; Positive test for chronic hepatitis B infection at screening, defined as either:; Severe drug allergic history or anaphylaxis to 2 or more food products or medicine (including known sensitivity to acetaminophen/paracetamol, diphenhydramine or equivalent antihistamine, and methylprednisolone or equivalent glucocorticoid); Positive hepatitis B surface antigen (HBsAg), or b. Positive hepatitis B core (HBc) antibody (anti-HBc) plus negative hepatitis B surface (HBs) antibody (anti-HBs); Positive test for hepatitis C virus antibody; History of cancer, apart from squamous cell or basal cell carcinoma of the skin treated with documented success of curative therapy > 3 months prior to Day 1; History of active or latent tuberculosis (TB), or a positive QuantiFERON®-TB Gold test at screening, unless treatment for TB was completed per local guidelines. Participants with latent TB or a positive QuantiFERON®-TB Gold test who are actively on anti-TB treatment can enroll if they have completed at least one month of anti-TB treatment and intend to complete the full course of anti-TB treatment. Participants with an indeterminate QuantiFERON®-TB Gold test result can enroll if a repeat QuantiFERON®-TB Gold test is negative or a tuberculin skin test is negative; For participants who may undergo MRI scans:; Unable to undergo an MRI scan (e.g., hypersensitivity to Gd-containing MRI contrast agents, implanted pacemakers, defibrillators, or other metallic objects on or inside the body that limit performing MRI scans), or; Unable to tolerate or comply with the MRI procedure; B-cell counts < one-half of the lower limit of normal (LLN) for age according to the central laboratory; Receipt of rituximab or any experimental B-cell depleting agent within 6 months prior to screening unless B-cell counts have returned to ≥ one-half the LLN; Evidence of significant hepatic, renal, or metabolic dysfunction or significant hematological abnormality (one repeat test may be conducted to confirm results within the same screening period); Negative test for varicella zoster virus (VZV)-IgG.

ClinicalTrials.gov NCT05549258 · EU CTIS 2023-510007-22-00